Regenerative medicine company AVITA Therapeutics Inc. announced the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020.
Vineti and EVERSANA announced a partnership to improve access, affordability and patient support challenges in regenerative medicine.
With $76 million in financing, San Diego-based Autobahn Therapeutics is hitting the ground with a goal of developing regenerative medicines aimed at treating disorders of the central nervous system (CNS).
Cryoport Inc. and EVERSANA announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.
Smith & Nephew Plc will buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing.
South Korea’s Biostar Stem Cell Research Institute – jointly operated by Nature Cell and Rbio – announced that Trinity Clinic Fukuoka, a partner hospital in Japan, received approval for the application of regenerative medicine in Alzheimer’s disease and officially began stem cell treatment as of April 12.
Athersys Inc. and Mesoblast Ltd. are beginning final-stage trials in hundreds of patients that they – along with loyal investors – say could change the course of devastating stroke and heart failure.
The U.S. Food and Drug Administration announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.
Allergan Plc tried to reassure shareholders after losing a major patent ruling during October 2017 on its second-most important drug, the dry-eye treatment Restasis, downplaying the importance of the loss of revenue from the drug.
The U.S. FDA is stepping up efforts to better regulate an emerging field of medicine that holds significant promise for curing some of the most troubling diseases by using the body’s own cells.